Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.

ABSTRACT: Chromosomal rearrangements of the NTRK genes generate kinase fusions that are targetable oncogenic drivers in diverse adult and pediatric malignancies. Despite robust clinical response to targeted NTRK inhibition, the emergence of therapeutic resistance poses a formidable clinical challenge. Here we report the characterization of an ETV6-NTRK3 fusion-driven pediatric glioma that progressed through NTRK-targeted treatments with entrectinib and selitrectinib. Genetic analysis of multifocal recurrent/resistant lesions identified a previously uncharacterized NTRK3 p.G623A and a known p.G623E resistance mutation, in addition to other alterations of potential pathogenic impact. Functional studies using heterologous reconstitution model systems and patient-derived tumor cell

SUBMITTER: Keddy C 

PROVIDER: S-EPMC8559620 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature